A quantitative analysis of kinase inhibitor selectivity

The protein kinase complement of the human genome

Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145 · see citing works

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802 · see citing works

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,019 · see citing works

SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1

Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R., & Lee, J. C. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00357-f · Cited by 2,086 · see citing works

Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

Joensuu, H., Roberts‎, P., Sarlomo‐Rikala, M., Andersson, L. C., Tervahartiala, P. O., Tuveson, D. A., Silberman, S., Capdeville, R., Dimitrijević, S., Druker, B. J., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,030 · see citing works

A small molecule–kinase interaction map for clinical kinase inhibitors

Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,901 · see citing works

The specificities of protein kinase inhibitors: an update

BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1× · see citing works

Discovery of N -(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D. J., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,303 · see citing works

Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors

Buchdunger, E., Cioffi, C. L., Law, N. M., Stover, D. R., Ohno-Jones, S., Druker, B. J., & Lydon, N. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,272 · see citing works

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D. Y., Hassell, A. M., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K. E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,130 · see citing works

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor

Heinrich, M. C., Griffith, D., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,066 · see citing works

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Böesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,036 · see citing works

Features of Selective Kinase Inhibitors

Knight, Z. A., & Shokat, K. M. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.04.011 · Cited by 663 · see citing works

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

Ohren, J. F., Chen, H., Pavlovsky, A. G., Whitehead, C. E., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C. A., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 635 · see citing works

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 550 · see citing works

Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3 Z )-ylidenemethyl]-2,4- dimethyl-1 H -pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase

Sun, L., Liang, C., Shirazian, S., Zhou, Y. G., Miller, T. M., Cui, J., Fukuda, J. Y., Chu, J.-Y., Nematalla, A. S., Wang, X., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204183 · Cited by 532 · see citing works

Targeting Tyrosine Kinases in Cancer: The Second Wave

Baselga, J. M. (2006) · Science · doi:10.1126/science.1125951 · Cited by 478 · see citing works

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

Giles, F. J., Cortes, J. E., Jones, D. M., Bergstrom, D. A., Kantarjian, H. M., & Freedman, S. J. (2006) · Blood · doi:10.1182/blood-2006-05-025049 · Cited by 365 · see citing works

Roscovitine Targets, Protein Kinases and Pyridoxal Kinase

Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M. H. M., Coburn, S. P., Tang, L., Jiang, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500806200 · Cited by 357 · see citing works

(S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno- 1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and Related Analogues: Isozyme Selective Inhibitors of Protein Kinase Cβ

Jirousek, M. R., Gillig, J. R., Gonzalez, C. M., Heath, W. F., McDonald, J. H., Neel, D. A., Rito, C. J., Singh, U. P., Stramm, L. E., Melikian-Badalian, A., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950588y · Cited by 340 · see citing works

Mechanisms of drug inhibition of signalling molecules

Sebolt, J. S., & English, J. M. (2006) · Nature · doi:10.1038/nature04874 · Cited by 306 · see citing works

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

Trudel, S., Li, Z.-H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. (2004) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 302 · see citing works

Gini Coefficient: A New Way To Express Selectivity of Kinase Inhibitors against a Family of Kinases

Graczyk, P. P. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070562u · Cited by 213 · see citing works

An efficient rapid system for profiling the cellular activities of molecular libraries

Melnick, J. S., Janes, J. O., Kim, S., Chang, J., Sipes, D. G., Gunderson, D., Jarnes, L., Matzen, J., Garcia, M. E., Hood, T. L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511292103 · Cited by 188 · see citing works

Kinomics—structural biology and chemogenomics of kinase inhibitors and targets

Vieth, M., Higgs, R. E., Robertson, D. H., Shapiro, M. J., Gragg, E. A., & Hemmerle, H. (2003) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.028 · Cited by 175 · see citing works

Design and Discovery of Small Molecules Targeting Raf-1 Kinase

Lowinger, T. B., Riedl, B., Dumas, J., et al. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023393125 · Cited by 148 · see citing works

Contrasting actions of staurosporine, a protein kinase C inhibitor, on human neutrophils and primary mouse epidermal cells.

SAKO, T., Tauber, A. I., Jeng, A. Y., et al. (1988) · PubMed · Cited by 120 · see citing works

From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents

Morin, M. J. (2000) · Oncogene · doi:10.1038/sj.onc.1204102 · Cited by 120 · see citing works

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

Allen, L. F., Lenehan, P. F., Eiseman, I. A., Elliott, W. L., & Fry, D. J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70122-x · Cited by 106 · see citing works

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

Allen, L. F., Lenehan, P. F., Eiseman, I. A., et al. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.34049 · Cited by 71 · see citing works

Sorafenib in Renal Cell Carcinoma

Flaherty, K. T. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2063 · Cited by 59 · see citing works

The second wave in kinase cancer drugs

Garber, K. (2006) · Nature Biotechnology · doi:10.1038/nbt0206-127 · Cited by 58 · see citing works

The Second Wave.

Taylor, C. R. (2002) · Cited by 54 · see citing works

Molecular basis for specificity in the druggable kinome: sequence-based analysis

Chen, J., Zhang, X., & Fernández, A. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btl666 · Cited by 47 · see citing works

High Affinity Targets of Protein Kinase Inhibitors Have Similar Residues at the Positions Energetically Important for Binding

Sheinerman, F. B., Giraud, E., & Laoui, A. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.074 · Cited by 44 · see citing works

Drug repurposing: progress, challenges and recommendations

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718 · see citing works

Modes of resistance to anti-angiogenic therapy

Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · see citing works

Comprehensive analysis of kinase inhibitor selectivity

Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409 · see citing works

Cellular senescence in aging and age-related disease: from mechanisms to therapy

Childs, B. G., Durik, M., Baker, D. J., & van Deursen, J. M. (2015) · Nature Medicine · doi:10.1038/nm.4000 · Cited by 2,363 · see citing works

Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum

Bendall, S. C., Simonds, E. F., Qiu, P., Amir, E.-A. D., Krutzik, P. O., Finck, R., Bruggner, R. V., Melamed, R., Trejo, A., Ornatsky, O. I., et al. (2011) · Science · doi:10.1126/science.1198704 · Cited by 2,279 · see citing works

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266 · see citing works

The role of JAK/STAT signaling pathway and its inhibitors in diseases.

Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010 · see citing works

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. (2011) · Nature Biotechnology · doi:10.1038/nbt.2017 · Cited by 919 · see citing works

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead

Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923 · see citing works

The target landscape of clinical kinase drugs

Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854 · see citing works

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732 · see citing works

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708 · see citing works

Src kinases as therapeutic targets for cancer

Kim, L. C., Song, L., & Haura, E. B. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.129 · Cited by 700 · see citing works

Targeting the cancer kinome through polypharmacology

Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674 · see citing works

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620 · see citing works

Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators

Bodenmiller, B., Zunder, E. R., Finck, R., Chen, T. J., Savig, E. S., Bruggner, R. V., Simonds, E. F., Bendall, S. C., Sachs, K., Krutzik, P. O., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2317 · Cited by 546 · see citing works

Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase

Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517 · see citing works

Small-molecule kinase inhibitors: an analysis of FDA-approved drugs

Wu, P., Nielsen, T. E., & Clausen, M. H. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.008 · Cited by 457 · see citing works

The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer

Yong, H.-Y., Koh, M.-S., & Moon, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903321490 · Cited by 422 · see citing works

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader

Huang, H.-T., Dobrovolsky, D., Paulk, J., Yang, G., Weisberg, E. L., Doctor, Z. M., Buckley, D. L., Cho, J.-H., Ko, E., Jang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.005 · Cited by 437 · see citing works

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines

Yu, C., Mannan, A. M., Yvone, G. M., Ross, K. N., Zhang, Y.-L., Marton, M. A., Taylor, B. R., Crenshaw, A., Gould, J. Z., Tamayo, P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3460 · Cited by 362 · see citing works

Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384 · see citing works

Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes

Zhao, Q., Ouyang, X., Wan, X., Gajiwala, K. S., Kath, J. C., Jones, L. H., Burlingame, A. L., & Taunton, J. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b08536 · Cited by 388 · see citing works

Comprehensive characterization of the Published Kinase Inhibitor Set

Elkins, J. M., Fedele, V., Szklarz, M., Abdul Azeez, K. R., Salah, E., Mikolajczyk, J., Romanov, S., Sepetov, N., Huang, X.-P., Roth, B. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3374 · Cited by 323 · see citing works

Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development

Donovan, K. A., Ferguson, F. M., Bushman, J. W., Eleuteri, N. A., Bhunia, D., Ryu, S., Tan, L., Shi, K., Yue, H., Liu, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.038 · Cited by 359 · see citing works

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis

Di Paolo, J. A., Huang, T., Balazs, M., Barbosa, J., Barck, K. H., Bravo, B. J., Carano, R. A. D., Darrow, J., Davies, D. R., DeForge, L. E., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.481 · Cited by 340 · see citing works

Information retrieval and text mining technologies for chemistry

Krallinger, M., Rabal, O., Lourenço, A., Oyarzabal, J., & Valencia, A. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00851 · Cited by 281 · see citing works

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Shah, K. N., Bhatt, R., Rotow, J., Rohrberg, J., Olivas, V., Wang, V. E., Hemmati, G., Martins, M. M., Maynard, A., Kuhn, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0264-7 · Cited by 286 · see citing works

NEMO and RIP1 Control Cell Fate in Response to Extensive DNA Damage via TNF-α Feedforward Signaling

Biton, S., & Ashkenazi, A. (2011) · Cell · doi:10.1016/j.cell.2011.02.023 · Cited by 262 · see citing works

Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy

Ellis, L. M., & Hicklin, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5287 · Cited by 257 · see citing works

Lung inflammation caused by inhaled toxicants: A review

Wong, J., Magun, B., & Wood, L. (2016) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s106009 · Cited by 193 · see citing works

FUS is Phosphorylated by DNA-PK and Accumulates in the Cytoplasm after DNA Damage

Deng, Q., Holler, C. J., Taylor, G., Hudson, K. F., Watkins, W., Gearing, M., Ito, D., Murray, M. E., Dickson, D. W., Seyfried, N. T., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0172-14.2014 · Cited by 161 · see citing works

Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase

Zhao, Q., Ren, C., Liu, L., Chen, J., Shao, Y., Sun, N., Sun, R., Kong, Y., Ding, X., Zhang, X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01264 · Cited by 134 · see citing works

Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo

Tanimoto, A., Ogawa, Y., Oki, C., Kimoto, Y., Nozawa, K., Amano, W., Noji, S., Shiozaki, M., Matsuo, A., Shinozaki, Y., et al. (2015) · Inflammation Research · doi:10.1007/s00011-014-0782-9 · Cited by 111 · see citing works

Midostaurin: a magic bullet that blocks mast cell expansion and activation

Valent, P., Akin, C., Hartmann, K., George, T. I., Sotlar, K., Peter, B., Gleixner, K. V., Blatt, K., Sperr, W. R., Manley, P. W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx290 · Cited by 79 · see citing works

Screening for covalent inhibitors using DNA-display of small molecule libraries functionalized with cysteine reactive moieties

Zambaldo, C., Daguer, J.-P., Saarbach, J., Barluenga, S., & Winssinger, N. (2016) · MedChemComm · doi:10.1039/c6md00242k · Cited by 75 · see citing works

Life Beyond Kinases: Structure-Based Discovery of Sorafenib as Nanomolar Antagonist of 5-HT Receptors

Lin, X., Huang, X.-P., Chen, G., Whaley, R., Peng, S., Wang, Y., Zhang, G., Wang, S. X., Wang, S., Roth, B. L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300338m · Cited by 73 · see citing works

Large-scale cytological profiling for functional analysis of bioactive compounds

Woehrmann, M. H., Bray, W. M., Durbin, J. K., Nisam, S. C., Michael, A. K., Glassey, E., Stuart, J. M., & Lokey, R. S. (2013) · Molecular BioSystems · doi:10.1039/c3mb70245f · Cited by 62 · see citing works

First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure

Zwirner, S., Abu Rmilah, A. A., Klotz, S., Pfaffenroth, B., Kloevekorn, P., Moschopoulou, A. A., Schuette, S., Haag, M., Selig, R., Li, K., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.023 · Cited by 65 · see citing works

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

Peter, B., Winter, G. E., Blatt, K., Bennett, K. L., Stefanzl, G., Rix, U., Eisenwort, G., Hadzijusufovic, E., Gridling, M., Dutreix, C., et al. (2016) · Leukemia · doi:10.1038/leu.2015.242 · Cited by 63 · see citing works

Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-<i>d</i>]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family

Smaill, J. B., Gonzales, A. J., Spicer, J. A., Lee, H., Reed, J. E., Sexton, K., Althaus, I. W., Zhu, T., Black, S. L., Blaser, A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00883 · Cited by 63 · see citing works

Enzastaurin: A lesson in drug development

Bourhill, T., Narendran, A., & Johnston, R. N. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.003 · Cited by 55 · see citing works

Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs

Heinzlmeir, S., Kudlinzki, D., Sreeramulu, S., Klaeger, S., Gande, S. L., Linhard, V., Wilhelm, M., Qiao, H., Helm, D., Ruprecht, B., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00709 · Cited by 56 · see citing works

JUN is important for ocular hypertension-induced retinal ganglion cell degeneration

Syc-Mazurek, S. B., Fernandes, K. A., & Libby, R. T. (2017) · Cell Death &amp; Disease · doi:10.1038/cddis.2017.338 · Cited by 53 · see citing works

Targeting dementias through cancer kinases inhibition

Fagiani, F., Lanni, C., Racchi, M., & Govoni, S. (2020) · Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions · doi:10.1002/trc2.12044 · Cited by 43 · see citing works

Paradoxical activation of c-Src as a drug-resistant mechanism

Higuchi, M., Ishiyama, K., Maruoka, M., Kanamori, R., Takaori-Kondo, A., & Watanabe, N. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108876 · Cited by 31 · see citing works

TNF-α-mediated suppression of Leydig cell steroidogenesis involves DAX-1

Sadasivam, M., Ramatchandirin, B., Balakrishnan, S., & Prahalathan, C. (2015) · Inflammation Research · doi:10.1007/s00011-015-0835-8 · Cited by 33 · see citing works

Presence and utility of intrinsically disordered regions in kinases

Kathiriya, J. J., Pathak, R. R., Clayman, E., Xue, B., Uversky, V. N., & Davé, V. (2014) · Molecular BioSystems · doi:10.1039/c4mb00224e · Cited by 30 · see citing works

SHEDding light on the role of Pragmin pseudo-kinases in cancer.

Roche, S., Lecointre, C., Simon, et al. (2019) · PubMed · Cited by 13 · see citing works

Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships

Laufkötter, O., Laufer, S., & Bajorath, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112641 · Cited by 8 · see citing works

PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor

Tamir, T. Y., Drewry, D. H., Wells, C. I., Major, M. B., & Axtman, A. D. (2020) · Scientific Reports · doi:10.1038/s41598-020-72869-9 · Cited by 15 · see citing works

Rigidification Dramatically Improves Inhibitor Selectivity for RAF Kinases

Assadieskandar, A., Yu, C., Maisonneuve, P., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00194 · Cited by 22 · see citing works

Structure Activity Relationship Studies around DB18, a Potent and Selective Inhibitor of CLK Kinases

Brahmaiah, D., Bhavani, A. K. D., Aparna, P., et al. (2022) · Molecules · doi:10.3390/molecules27196149 · Cited by 5 · see citing works